3 results
Approved WMOCompleted
The primary objective is to demonstrate non-inferiority of patients bilaterally implanted with the AcrySof® IQ ReSTOR® +2.5 D MIOL to AcrySof® IQ ReSTOR® +2.5 D MIOL in the dominant eye and AcrySof® IQ ReSTOR® +3.0 D in the fellow eye in binocular…
Approved WMOCompleted
To assess the impact of treatment with Lanreotide versus current standard of treatment on output reduction in patients with high output enterocutaneous fistula or high-output stoma.
Approved WMOCompleted
Primary:To compare the effect of UMEC/VI (62.5/25 mcg once daily) with UMEC (62.5 mcg once daily) on lung functionSecondary:To compare UMEC/VI, UMEC with salmeterol (50 mcg twice daily) on patient reported outcomes and on other COPD efficacy…